Results 81 to 90 of about 24,935 (185)

Comparison of oseltamivir and oseltamivir carboxylate concentrations in venous plasma, venous blood, and capillary blood in healthy volunteers.

, 2013
Oseltamivir and oseltamivir carboxylate concentrations were measured in venous plasma, venous blood, and capillary blood taken simultaneously from 24 healthy volunteers.
Blessborn, D, Pukrittayakamee, S, Jittmala, P, Hanpithakpong, W, Lindegardh, N, Instiaty, I, Tarning, J, White, NJ, White, Nicholas, Blessborn, Daniel   +9 more
core   +1 more source

Trends in Anti-Influenza Drug Prescription and Adverse Drug Reaction Reporting After the Lifting of Oseltamivir Prescribing Restrictions in Pediatric Outpatients: An Ecological Study Using the MDV Analyzer® And the Japanese Adverse Drug Event Report Database

Drugs - Real World Outcomes
Background Abnormal behavior after oseltamivir administration has been reported in the media; in 2007, the package insert for oseltamivir phosphate was revised to restrict its administration to individuals aged over 10 years.
Misaki Tokunaga, Daisuke Kikuchi, Aoi Noda, Sachiko Oikawa, Makoto Shiozawa, Hiroaki Hino, Ryosuke Miura, Kensuke Usui, Taku Obara, Kouji Okada   +9 more
doaj   +1 more source

Study population in the azithromycin-oseltamivir combination therapy and oseltamivir monotherapy groups.

, 2014
Study population in the azithromycin-oseltamivir combination therapy and oseltamivir monotherapy groups.
Masafumi Seki (535641), Yoshitomo Morinaga (535644), Shintaro Kurihara (527221), Shigeru Kohno (278864), Kosuke Kosai (535643), Shigeki Nakamura (358081), Koichi Izumikawa (535642), Takayoshi Tashiro (535648), Misuzu Tsukamoto (535646), Taiga Miyazaki (278860), Yoshifumi Imamura (535645), Katsunori Yanagihara (535647), Hiroshi Kakeya (278863)   +12 more
core   +1 more source

Efficacy and safety of intravenous peramivir versus oral oseltamivir in the treatment of influenza in children: A meta-analysis

Journal of Clinical Virology Plus
Objective: To investigate the efficacy and safety of intravenous peramivir compared to oral oseltamivir for pediatric influenza by a method of meta-analysis.
Jie Yuan, Shuhua An, Zhongfu Zhang
doaj   +1 more source

Laboratory data for the azithromycin-oseltamivir combined therapy and oseltamivir monotherapy groups.

, 2014
Laboratory data for the azithromycin-oseltamivir combined therapy and oseltamivir monotherapy groups.
Masafumi Seki (535641), Yoshitomo Morinaga (535644), Shintaro Kurihara (527221), Shigeru Kohno (278864), Kosuke Kosai (535643), Shigeki Nakamura (358081), Koichi Izumikawa (535642), Takayoshi Tashiro (535648), Misuzu Tsukamoto (535646), Taiga Miyazaki (278860), Yoshifumi Imamura (535645), Katsunori Yanagihara (535647), Hiroshi Kakeya (278863)   +12 more
core   +1 more source

Healthcare Provider Education on Oseltamivir Resistance and Centers for Disease Control and Prevention Prescription Guidelines of Oseltamivir for Influenza [PDF]

, 2021
Background: Oseltamivir treatment for influenza should begin within 48 hours of symptom onset; however, there is no significant benefit or data supporting the use of Oseltamivir beyond the 48-hour window in otherwise healthy adults.
Kazempoor, Deeba
core  

Systematic review of influenza resistance to the neuraminidase inhibitors

BMC Infectious Diseases, 2011
Background Antivirals play a critical role in the prevention and the management of influenza. One class of antivirals, neuraminidase inhibitors (NAIs), is effective against all human influenza viruses. Currently there are two NAI drugs which are licensed
Boivin Guy, Awad Tahany, Thorlund Kristian, Thabane Lehana   +3 more
doaj   +1 more source

One-way sensitivity analyses tornado diagram: Empiric treatment with oseltamivir vs. post RIDT treatment with oseltamivir.

, 2016
One-way sensitivity analyses tornado diagram: Empiric treatment with oseltamivir vs. post RIDT treatment with oseltamivir.
Jiuhong Wu (2615215), Seng Chuen Tan (2615218), Tengbin Xiong (2615212), Kunling Shen (309945)   +3 more
core   +1 more source

Improvement of influenza-related symptoms in the azithromycin-oseltamivir combination therapy and oseltamivir monotherapy groups.

, 2014
Improvement of influenza-related symptoms in the azithromycin-oseltamivir combination therapy and oseltamivir monotherapy groups.
Masafumi Seki (535641), Yoshitomo Morinaga (535644), Shintaro Kurihara (527221), Shigeru Kohno (278864), Kosuke Kosai (535643), Shigeki Nakamura (358081), Koichi Izumikawa (535642), Takayoshi Tashiro (535648), Misuzu Tsukamoto (535646), Taiga Miyazaki (278860), Yoshifumi Imamura (535645), Katsunori Yanagihara (535647), Hiroshi Kakeya (278863)   +12 more
core   +1 more source

In Silico Profiling of Binding Affinities of Hybrid Molecules of Oseltamivir carboxamides cross-linked with Hydroxamic acid as possible Anti-influenza agents

Al-Mustansiriyah Journal of Pharmaceutical Sciences
Influenza is an infectious respiratory disease caused by the influenza virus and is a significant global public health concern. This infection displays a tendency for recurring outbreaks during specific seasons and occasional epidemics.
Sumia Samer Tayah, Shakir Mahmood Alwan, Kenza Mansoor   +2 more
doaj   +1 more source